Inclusion Criteria:  Histologically or radiologically confirmed colorectal cancer metastases to the liver Patient is able to have either CT or MRI imaging Hepatic tumor burden ≥50% of total tumor burden Hepatic tumor burden ≤50% of total liver volume Not suitable for treatment by resection or percutaneous ablation at time of TACE treatment Life expectancy ≥ 3 months WHO performance status ≤ 2  Exclusion Criteria:  Previous treatment with any form of hepatic transarterial embolization Total bilirubin ≥ 3.0 mg/dL Any contraindication for irinotecan administration Partial or complete thrombosis of the main portal vein Cardiovascular or respiratory failure Any other condition deemed exclusionary by the Investigator